Skip to main content

Two Additional Lawsuits Filed Seeking to Block BGI Buy of Complete Genomics

NEW YORK (GenomeWeb News) – Two additional lawsuits have been filed seeking to block BGI's $117.6 million purchase of Complete Genomics.

In documents filed with the US Securities and Exchange Commission on Tuesday, Complete Genomics disclosed the two new lawsuits, which follow two earlier lawsuits also seeking to stop the sale of the company to BGI.

One lawsuit, Chad Gerber v. Clifford A. Reid, et al, was filed on Sept. 28 in the Delaware court of Chancery. Another lawsuit, Saba Saleemi v. Complete Genomics, Inc., et al, was filed on Oct. 1 also in the Delaware Court of Chancery.

In addition to Complete Genomics, its directors and BGI are named as defendants in both cases, which allege breach of fiduciary duties. Both lawsuits seek, among other things, a preliminary and permanent injunction against the deal. They also seek class action status.

Complete Genomics and BGI said at the time it was announced that the acquisition is expected to be completed in early 2013.

In Wednesday afternoon trading on the Nasdaq, Complete Genomics' shares were flat at $3.10.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.